Evidence map›Paper›PMID 42571145›Full record

ArticleMultiple sclerosis journal - experimental, translational and clinical

Effectiveness of a digital health application (

Björn Meyer, Gereon Nelles, Linda Betz, Arnfin Bergmann, Kamila Jauch-Chara, Nicole Krause, Karin Riemann, Barbara von Glasenapp, Christoph Heesen

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06090305 (Effectiveness of a Digital Health Application for Multiple Sclerosis), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06090305 nacompletednot on this map

Effectiveness of a Digital Health Application for Multiple Sclerosis (Levidex): Randomized Controlled Trial

TypeinterventionalSponsorGaia AGRan2023 to 2024Enrolled470ConditionsMultiple SclerosisArmslevidex, Control, treatment as usual (TAU)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Björn MeyerResearch and Development Department, GAIA Group, Hamburg, DE, Germany.ORCID https://orcid.org/0000-0003-1100-0260
Gereon NellesNeurology, Neuromed-Campus Hohenlind, Cologne, DE, Germany.
Linda BetzResearch and Development Department, GAIA Group, Hamburg, DE, Germany.ORCID https://orcid.org/0000-0003-1741-4069
Arnfin BergmannNeuroTransData, Neuburg an der Donau, BY, Germany.
Kamila Jauch-CharaPsychiatry, Psychosomatic Medicine and Psychotherapy, Vincera Kliniken Bad Waldsee, Bad Waldsee, DE, Germany.
Nicole KrauseInstitute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, DE, Germany.ORCID https://orcid.org/0000-0001-6681-7054
Karin RiemannInstitute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, DE, Germany.ORCID https://orcid.org/0000-0002-0779-2640
Barbara von GlasenappInstitute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, DE, Germany.ORCID https://orcid.org/0000-0002-3820-9059
Christoph HeesenInstitute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, DE, Germany.ORCID https://orcid.org/0000-0001-8131-9467

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: People with multiple sclerosis (pwMS) often experience impaired quality of life (QoL) despite receiving standard care. Digital therapeutics (DTx) may offer support, but prior trials yielded mixed results, possibly due to active controls and high baseline QoL. Objectives: We evaluated a DTx (levidex) as an adjunct to treatment as usual (TAU) in pwMS with impaired QoL. Methods: In this pragmatic, online randomized controlled trial (LAMONT; NCT06090305), Results: Compared with TAU, levidex + TAU improved multiple sclerosis-specific QoL at 6 months (baseline-adjusted mean difference -0.10; 95% CI -0.18 to -0.03; Conclusions: In pwMS with impaired QoL, adding the scalable DTx levidex to TAU yields meaningful improvements in QoL and functioning.

Indexed as

complex interventiondigital health applicationMultiple sclerosispatient-reported outcomes (PROMs)quality of liferandomized controlled trial

Identifiers

PMID42571145
PMCPMC13451721

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.